Psoriasis treatment patterns: Results of a cross-sectional survey of dermatologists - 24/04/13
, Seth R. Stevens a, Mark Lebwohl, MD f
Reprint requests: Kathleen M. Fox, PhD, PO Box 543, Monkton, MD 21111.Abstract |
Objective |
The study evaluated community physician prescribing patterns for patients with psoriasis.
Methods |
US dermatologists actively practicing general dermatology and treating 10 or more patients with psoriasis/mo were interviewed (n = 90) in April and June 2006 and they recruited 8 to 10 consecutive patients for record review (n = 895, mean age = 46 years, 51% men). Proportion of patients treated with systemic, biologic, or topical therapy as reported by the dermatologist and recorded in the records was assessed by psoriasis severity.
Results |
Among patients with severe psoriasis (body surface area affected > 10%), 56% to 63% received systemic therapy (including biologics) or phototherapy and 37% to 44% received topical therapy only. Dermatologists reported prescribing biologics to 41% of patients with severe disease compared with patient records where 27% to 34% of body surface area = 11% to 40% and 36% of body surface area greater than 40% patients received biologics.
Limitations |
Because of the small sample, eligibility criteria, and voluntary interview, selection bias may have occurred.
Conclusions |
Some dermatologists are prescribing systemic therapy for the majority of their patients with severe psoriasis but a gap in treatment remains for about 40% who received topical therapy alone.
Le texte complet de cet article est disponible en PDF.Plan
| Supported in part by Amgen Inc. |
|
| Disclosure: Drs Patel and Stevens are employees of Amgen Inc. Dr Horn was an employee of the National Psoriasis Foundation and consulted with the International Psoriasis Council while a portion of this work was done. Mr Lobosco and the Adelphi Group received research funds from Amgen Inc to conduct and analyze the survey. Dr Fox received research funds from Amgen Inc to analyze the survey data and develop the manuscript, and consults with AstraZeneca Pharmaceuticals LP and Novartis Pharmaceuticals. Dr Lebwohl has been a consultant and/or speaker for Abbott, Amgen, Astellas, Centocor, Connetics, Galderma, Genentech, Medicis, Novartis, Pharmaderm, Stiefel, UCB Pharma, and Warner Chilcott. The National Psoriasis Foundation receives unrestricted funding from Abbott Immunology, Amgen Inc, Astellas Pharma Inc, Barrier Therapeutics, Beiersdorf, Centocor, Daavlin, Galderma Laboratories, Genentech, National Biologic Corporation, Neutrogena, Photomedex, Stiefel Laboratories, Warner Chilcott, and Wyeth. The Adelphi Group receives unrestricted funding from international and US pharmaceutical companies. |
Vol 58 - N° 6
P. 964-969 - juin 2008 Retour au numéro
Article précédent
- Classification of facial psoriasis based on the distributions of facial lesions
- Seung Man Woo, Jung Won Choi, Hyun Sun Yoon, Seong Jin Jo, Jai Il Youn
- To test or not to test? An evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis
- William Huang, Kelly M. Cordoro, Sarah L. Taylor, Steven R. Feldman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?